✦ LIBER ✦

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

✍ Scribed by Akira Tsuburaya, Satoshi Morita, Yasuhiro Kodera, Michiya Kobayashi, Kohei Shitara, Kensei Yamaguchi, Takaki Yoshikawa, Kazuhiro Yoshida, Shigefumi Yoshino, Jun-ichi Sakamoto

Book ID: 119897363
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 157 KB
Volume: 12
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-12-307

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6600 POSTER A Randomized, Multicenter, O

6600 POSTER A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of Capecitabine Plus Paclitaxel Followed by Capecitabine Maintenance (PX-X) With Capecitabine Plus Cisplatin (XP) as a First-line Chemotherapy for Recurrent or Metastatic Gastric Cancer (PAC-C Study)

✍ Zhang, X.; Shen, L.; Lu, Z.; Hu, B.; Fan, Q.; Li, W.; Liu, W.; Liu, T.; Pan, Y.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB